Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review

Rothbart, Rachel; Stein, Dan J.

doi:10.1517/14656566.2014.972936

Cited by 17 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, fluvoxamine treatment dose of 50 mg/day might be too low for definition of SSRI resistance. It is reported that the existing trials of TTM have very small sample sizes, and the body of evidence is of low quality, mostly clinical trials where a target was more than 18 years old (only one trial included a 16 year-old-subject) [2]. So, the appropriate capacity of fluvoxamine, other SSRI, atypical, or typical antipsychotics for treatment of TTM in children and adolescents is still unknown.…”

Section: Case Presentationmentioning

confidence: 99%

“…TTM is associated with distress as well as with social and occupational impairment [1]. Accumulating evidence suggests that pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics, opioid-antagonists, or glutamate modulators has the potential to improve TTM in adults [2]. Recent empirical studies have also pointed to the potential of cognitive behavioral therapy (CBT) for the treatment of childhood TTM [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of puberty trichotillomania with low-dose aripiprazole

Sasaki

Iyo

2015

Ann Gen Psychiatry

View full text Add to dashboard Cite

The present case is of a 14-year-old female with trichotillomania (TTM) that was treated with a low dose of aripiprazole (ARP) 1.5 mg/day. To our knowledge, this is the first published report to show an improvement of pubertal TTM using an ultra-low dose of ARP. In this case, a 50-mg fluvoxamine monotherapy for 2 years and a subsequent 4-month comprehensive cognitive behavioral therapy (CBT) monotherapy did not improve her hair-pulling symptoms. However, the treatment with a low-dose ARP of 1.5 mg/day dramatically improved her TTM symptoms without extrapyramidal symptoms. In this regard, low-dose ARP treatment for TTM might be a safe alternative to antidepressants, which carry the risk of agitation with suicidal ideation in adolescents.

show abstract

Section: Case Presentationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Treatment of puberty trichotillomania with low-dose aripiprazole

Sasaki

Iyo

2015

Ann Gen Psychiatry

View full text Add to dashboard Cite

show abstract

“…But, a significant stressful life event was not detected in this case. Although SSRIs continue to be used for therapeutic purposes in cases of trichotillomania, the results from studies regarding its effectiveness are negative [17]. Indeed, trichotillomania was reported to develop in association with fluoxetine use in a 7year-old boy [7], and exacerbation of trichotillomania symptoms with fluoxetine use was also reported in a girl of the same age to be [18].…”

Section: Discussionmentioning

confidence: 99%

Probable emergence of symptoms of trichotillomania by atomoxetine: a case report

Ayaydın

2018

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. Atomoxetine is the first nonpsychostimulant agent approved by the Food and Drug Administration for the treatment of ADHD. Trichotillomania (TTM) is an obsessivecompulsive and related disorder characterized by a long-term urge that results in the pulling out of one's hair from any part of his/her body. Studies have implicated dopaminergic and serotonergic dysfunction in the aetiology of TTM. We report a male patient with ADHD developing of symptoms of TTM following atomoxetine use. Atomoxetine indirectly affects dopamine levels in the mesolimbic dopamine system, similarly to methylphenidate/ amphetamine, and can thus lead to hair pulling behaviour. Further studies concerning the potential adverse effects of atomoxetine, such as the development of TTM, are now needed.

show abstract

“…Selective serotonin reuptake inhibitors, in general, show negative results and, in case reports, have been potentiated with atypical antipsychotics. Despite their widespread use, they do not appear to be effective in trials, particularly in monotherapy 26,[30][31][32]34 are presented in Table 4.…”

Section: Secondary Psychiatric Disordersmentioning

confidence: 99%

Psychopharmacology in dermatology: Treatment of primary psychiatric conditions in dermatology

Torales

Melgarejo

González

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The role of psychotropic drugs in psychodermatology is still debatable, due to the quality of the evidence that supports it. There are several case reports and open trials with variable results. There is an additional difficulty in finding therapists trained in effective psychotherapy techniques, justify the need for more research on the available pharmacological options. The present review emphasizes pharmacological treatment in psychodermatology, specifically in cases of primary psychiatric disorders that are expressed with self‐inflicted cutaneous signs and symptoms, in which drugs can play a central role in ameliorating symptoms or be useful in combination with psychotherapeutic approach of these disorders.

show abstract

Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review

Cited by 17 publications

References 33 publications

Treatment of puberty trichotillomania with low-dose aripiprazole

Treatment of puberty trichotillomania with low-dose aripiprazole

Probable emergence of symptoms of trichotillomania by atomoxetine: a case report

Psychopharmacology in dermatology: Treatment of primary psychiatric conditions in dermatology

Contact Info

Product

Resources

About